Literature DB >> 23816048

Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment.

John G Routsias1, John D Goules, Georgios Charalampakis, Sotiria Tzima, Aristea Papageorgiou, Michael Voulgarelis.   

Abstract

OBJECTIVES: Sjögren's syndrome (SS), a chronic autoimmune disorder, particularly compromises the function of exocrine glands. Its association with lymphoma is well documented. Our aim was to systematically review the molecular, clinical, histopathologic, and therapeutic aspects of these SS-related malignant lymphoproliferations.
METHODS: The literature was searched for original articles published between 1968 and 2012 focusing on the risk factors for lymphoma development in Sjögren's syndrome using MEDLINE and PubMed. The search terms we used were "Sjögren's syndrome," "lymphoma," and "risk factors." All papers identified were English-language, full-text papers.
RESULTS: A low-grade marginal-zone lymphoma related to mucosa-associated lymphoid tissue is the commonest lymphoid neoplasia in SS. The majority of SS-associated lymphomas are characterized by localized stage, indolent clinical course, and recurrence in other extranodal sites. Although the transition from a chronic inflammatory condition to malignant lymphoma is a multistep process that is yet poorly understood, there is increasing evidence that chronic antigenic stimulation by an exoantigen or autoantigens plays an essential role in the development of SS-associated lymphoproliferation.
CONCLUSIONS: This review discusses the pathogenetic aspects of lymphomagenesis in SS. Recent advances in the treatment of lymphoma in SS are also stated.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Lymphoproliferation; Non-Hodgkin lymphoma; Salivary glands; Sjögren’s syndrome

Mesh:

Year:  2013        PMID: 23816048     DOI: 10.1016/j.semarthrit.2013.04.004

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  16 in total

Review 1.  Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies.

Authors:  Abha G Singh; Siddharth Singh; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2015-09-27       Impact factor: 7.580

Review 2.  Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren's syndrome patients: case series study and review of the literature.

Authors:  Vadim Romanovich Gorodetskiy; Natalya Alexandrovna Probatova; Stefka Gospodinova Radenska-Lopovok; Natalya Valerievna Ryzhikova; Yulia Vladimirovna Sidorova; Andrey Borisovich Sudarikov
Journal:  Rheumatol Int       Date:  2019-11-09       Impact factor: 2.631

Review 3.  Update on Pathogenesis of Sjogren's Syndrome.

Authors:  Pulukool Sandhya; Biji Theyilamannil Kurien; Debashish Danda; Robert Hal Scofield
Journal:  Curr Rheumatol Rev       Date:  2017

Review 4.  Adjuvants and lymphoma risk as part of the ASIA spectrum.

Authors:  Dana Butnaru; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 5.  Oral manifestations of systemic disease.

Authors:  S R Porter; V Mercadante; S Fedele
Journal:  Br Dent J       Date:  2017-11-10       Impact factor: 1.626

6.  Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Paige M Bracci; Yolanda Benavente; Jennifer J Turner; Ora Paltiel; Susan L Slager; Claire M Vajdic; Aaron D Norman; James R Cerhan; Brian C H Chiu; Nikolaus Becker; Pierluigi Cocco; Ahmet Dogan; Alexandra Nieters; Elizabeth A Holly; Eleanor V Kane; Karin E Smedby; Marc Maynadié; John J Spinelli; Eve Roman; Bengt Glimelius; Sophia S Wang; Joshua N Sampson; Lindsay M Morton; Silvia de Sanjosé
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

Review 7.  Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.

Authors:  Maria B Nishishinya; Claudia A Pereda; Santiago Muñoz-Fernández; José M Pego-Reigosa; Iñigo Rúa-Figueroa; José-Luis Andreu; Mónica Fernández-Castro; José Rosas; Estibaliz Loza Santamaría
Journal:  Rheumatol Int       Date:  2014-06-05       Impact factor: 2.631

8.  Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.

Authors:  A Alunno; F Carubbi; O Bistoni; S Caterbi; E Bartoloni; P Di Benedetto; P Cipriani; R Giacomelli; R Gerli
Journal:  Clin Exp Immunol       Date:  2016-03-03       Impact factor: 4.330

9.  Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren's syndrome.

Authors:  Sarah Benchabane; Mourad Belkhelfa; Houda Belguendouz; Sourour Zidi; Abdelhalim Boudjelida; Pierre Youinou; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2018-06-04       Impact factor: 4.473

10.  NOD and NOR mice exhibit comparable development of lacrimal gland secretory dysfunction but NOD mice have more severe autoimmune dacryoadenitis.

Authors:  Yaping Ju; Srikanth Reddy Janga; Wannita Klinngam; J Andrew MacKay; Dillon Hawley; Driss Zoukhri; Maria C Edman; Sarah F Hamm-Alvarez
Journal:  Exp Eye Res       Date:  2018-09-08       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.